Shingles vaccine study for people with autoimmune diseases
Part of Infections clinical trials.
This study looks at how well the shingles vaccine works in people with autoimmune inflammatory diseases. Researchers want to make sure the vaccine provides good protection for patients whose immune systems are affected by their condition or treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have an autoimmune inflammatory disease like lupus, Sjögren's syndrome, scleroderma, vasculitis, or another listed condition
- You are being treated at Hôpital Bichat in Paris
- You got a shingles vaccine between June 2025 and June 2026 (at least the first dose)
- A blood sample is available for testing
- You do not have an active cancer or a history of allergic reaction to vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the recombinant shingles vaccine in adults with autoimmune rheumatic diseases who are on certain mild medications. It aims to see if the vaccine is safe and effective for them.
This study tests how well the shingles vaccine works in people with weakened immune systems due to conditions like rheumatoid arthritis, cancer, or multiple sclerosis. It aims to see if the vaccine is safe and effective for these patients.
This study offers the Shingrix shingles vaccine for free to adults with inflammatory rheumatic diseases. It compares how well the vaccine works in people taking immune-suppressing drugs versus those not taking them.
This study tests a new shingles vaccine in people with psoriasis or myelofibrosis, some of whom take immune-modifying medications. Researchers want to understand how well the vaccine works and how the immune system responds in these groups.
This study tests a new vaccine to prevent shingles (a painful rash condition) in adults 50 and older. It checks how safe the vaccine is and how well it triggers the body's immune defense.
This trial tests a new shingles vaccine in healthy adults aged 50 to 65. Shingles can cause a painful rash, and the vaccine aims to prevent it.
Hear when a new Vaccination Varicella-zoster Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.